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Antimicrobial resistance (AMR) is a globally important one health threat. The impact of 29 
resistant infections on companion animals, and the potential public health implications of such 30 
infections, has not been widely explored,contribution of companion animal clinical AMR to 31 
public and animal health has not been widely explored, largely due to an absence of structured 32 
population-level data. 33 
Objectives 34 
We aimed to efficiently capture and repurpose antimicrobial susceptibility test (AST) results 35 
data from several veterinary diagnostic laboratories (VDLs) across the UK to facilitate national 36 
companion animal clinical AMR surveillance. We also sought to harness and genotypically 37 
characterise isolates of potential AMR importance from these laboratories. 38 
Methods 39 
We summarised AST results for 29,330 canine and 8,279 feline Enterobacteriaceae clinical 40 
isolates originating from companion animal clinical practice, performed between April 2016 41 
and July 2018 from four VDLs, with submissions from 2,237 UK veterinary practice sites.  42 
Results 43 
Escherichia coli (E. coli) was the most commonly isolated Enterobacteriaceae in dogs (69.4% 44 
of AST results, 95% confidence interval, CI, 68.7-70.0) and cats (90.5%, CI 89.8-91.3). Multi-45 
drug resistance was reported in 14.1% (CI 13.5-14.8) of canine and 12.0% (CI 11.1-12.9) of 46 
feline E. coli isolates. Referral practices were associated with increased E. coli 3rd generation≤ 47 
cephalosporin resistance odds (dogs: odds ratio 2.0, CI 1.2-3.4). We selected 95 E. coli isolates 48 
for whole genome analyses, of which seven belonged to sequence type 131, also carrying the 49 
plasmid-associated extended spectrum β-lactamase gene blaCTX-M-15. The plasmid-mediated 50 
colistin resistance gene mcr-9 was also identified for the first time in companion animals.  51 
Conclusions 52 
Linking clinical AMR data with genotypic characterisation represents an efficient means of 53 





Antimicrobial resistance (AMR) poses a significant global threat to animal and human health 56 
(O’Neill, 2016). The World Health Organisation (WHO) has identified Enterobacteriaceae to 57 
be of critical importance, due to worldwide dissemination of extended spectrum β-lactamases 58 
(ESBLs), ampicillin hydrolysing (AmpC) β-lactamases, and carbapenemases (Iredell et al., 59 
2016; Bezabih et al., 2021; Salgado-Caxito et al., 2021). Additionally, newly emerging 60 
resistance trends, for example mobile colistin resistance (Elbediwi et al., 2019; El-Sayed 61 
Ahmed et al., 2020), have led to increased reports of multi-drug resistant (Magiorakos et al., 62 
2012) and pan-resistant strains (Sun et al., 2016). 63 
 64 
To address these issues, national AMR surveillance in humans and production animals has been 65 
established (PHE, 2017; VMD, 2019). However, companion animal species have been 66 
arguably neglected, despite resistance developing in companion animals exposed to 67 
antimicrobial therapy (Schmidt et al., 2018), and transmission of pathogens and resistance 68 
between humans and companion animals (Lei et al., 2017). This oversight has partly been due 69 
to the companion animal veterinary diagnostic laboratory (VDL) sector being largely 70 
comprised of independent commercial laboratories, each utilising often bespoke information 71 
management systems (O’Neill et al., 2014), and different protocols for antimicrobial 72 
susceptibility testing (AST) (Marques et al., 2016). Such protocols largely focus on relatively 73 
time-consuming techniques for demonstrating phenotypic resistance. Recently, genomics-74 
based methodologies have unlocked a wealth of information pertaining to the development and 75 
dissemination of resistance genes in and between bacterial species (McCarthy et al., 2015). 76 
Though this has only begun to be explored in companion animals (Zhang, 2016), bacterial 77 
isolates disposed of by VDLs remain an untapped resource. 78 
 79 
Hence, the aim of this study was, using Enterobacteriaceae isolated from clinical samples of 80 
dogs and cats as an exemplar, to define national patterns of AST in companion animals, and 81 
factors associated with resistance. Further, we sought to develop a method by which 82 
Enterobacteriaceae isolates expressing resistance patterns of potential public health 83 
importance could be efficiently captured from VDLs for genotypic characterisation. We also 84 
sought to investigate the AST method and interpretation variation between VDLs, and to 85 
outline how such variation might impact on more detailed genotypic investigations as 86 
performed here. 87 
 88 
Materials and methods 89 
Antimicrobial susceptibility test data 90 
Clinical AST data were collated by the Small Animal Veterinary Surveillance Network 91 
(SAVSNET) from four UK VDLs (A-D) between 1st April 2016 and 31st July 2018, including 92 
a unique sample identifier; submitting veterinary practice site postcode; report date; animal 93 
species; breed; sex and neuter status; bacterial species isolated, and AST results. Sample 94 
type/site (supplied as free text) was manually categorised into urine, ear(s), oro-nasopharyngeal 95 
and respiratory sites, faeces, anal region including anal sacs, and other/mixed sites. SAVSNET 96 
holds ethical approval to collect such data from the University of Liverpool Ethics Committee 97 
(RETH0000964). 98 
 99 
The manner with which bacterial species were described varied between VDLs, ranging from 100 
genus-level (e.g., Escherichia) alone to species-level (e.g., Escherichia coli). Similarly, 101 
bacteria were speciated according to varying methodologies, ranging fromBacterial species 102 
were described variously to genus- and species-levels by commercial biochemical tests (VDLs 103 




Laboratories utilised disc diffusion (VDL B-D) or minimum inhibitory concentration (MIC) 105 
(VDL A) approaches, and used different interpretation guidelines (CLSI, EUCAST, BSAC). 106 
As some VDLs (B-D) only provided clinically interpreted AST results, analysis was restricted 107 
to interpreted results alone. Only antimicrobials associated with species-specific acquired 108 
resistance were summarised. Tested antimicrobials were grouped to class-level 109 
(Supplementary material 1); ‘intermediate’ results were classified as ‘sensitive’, with multi-110 
drug resistance (MDR) defined as resistance to three or more classes (Magiorakos et al., 2012). 111 
 112 
Veterinary practice site demographic data 113 
The Royal College of Veterinary Surgeons (RCVS) Veterinary Practice Directory(RCVS, 114 
2018) was interrogated on 12th October 2018, using R packages ‘rvest’ (Wickham, 2016)  and 115 
‘purrr’ (Henry, 2018),  to extract information for all UK veterinary practice sites (table 1); 116 
postcodes containing more than one site treating companion animals (n=148) were designated 117 
‘multi-site postcodes’. The National Statistics Postcode Look-up was used to provide 118 
geographical information, including urban/rural status (NSPL, 2015). 119 
 120 
Animal demographic data 121 
Dog and cat breeds were summarised to standardised breed terms, which were then grouped 122 
into genotypically similar groups. Three further breed groups were defined: crossbreeds, breeds 123 
not yet genetically classified (‘unclassified’), and breeds not recorded or recognisable 124 
(‘unknown’) (Singleton et al., 2020). 125 
 126 
Multidrug resistant isolate collection and storage 127 
Six VDLs (A-F) were approached regarding collection of Enterobacteriaceae isolates, of 128 
which three (A, E, F) participated. Submitted isolates needed to comply with one or more of 129 
the following criteria: (1) Phenotypic ESBL-producer, (2) MDR, or (3) non-susceptibility to 130 
one or more of the 3rd/4th generation cephalosporin, fluoroquinolone, polymyxin, or 131 
carbapenem classes. On receipt at the University of Liverpool, isolates (n=148) were incubated 132 
under aerobic conditions for 18-24 hours at 37⁰C on nutrient agar, and pure colonies stored at 133 
-80⁰C (MicrobankTM cryovial; Pro-Lab Diagnostics UK, UK). 134 
 135 
Phenotypic analyses 136 
To mitigate for protocol variation between VDLs, disc diffusion ASTs were undertaken on all 137 
received isolates according to CLSI guidelines (CLSI, 2008). Antimicrobial discs (MAST 138 
Diagnostics; Liverpool, UK) represented a range of antimicrobial classes (Supplementary 139 
material 2). Inhibition zones were measured after aerobic incubation at 37oC overnight, and 140 
classified as susceptible, intermediate or resistant, or ESBL-producing via a combination disc 141 
method (Supplementary material 2; MAST Diagnostics; Liverpool, UK) (CLSI, 2008) 142 
‘Intermediate’ results were considered ‘sensitive’. 143 
 144 
Genotypic analyses 145 
Crude nucleic acid extracts were prepared prior to PCR amplification, with isolates classified 146 
as E. coli via presence of the uidA (McDaniels et al., 1996) or uspA genes (Bekal et al., 2003) 147 
(Supplementary material 3). All isolates were tested for blaCTX-M (Boyd et al., 2004), with 148 
positive isolates characterised into blaCTX-M cluster groups 1, 2, or 9 (Batchelor et al., 2005; 149 
Hopkins et al., 2006; Carattoli et al., 2008). Isolates possessing blaCTX-M group 1 genes were 150 
characterised into blaCTX-M-1 or blaCTX-M-15 variants via real-time PCR (Isgren et al., 2019). All 151 
isolates were tested for presence of blaTEM, blaSHV or blaOXA (Dallenne et al., 2010), and those 152 




Perez and Hanson, 2002). All isolates were tested for presence of qnrA, qnrB, or qnrS, genes 154 
(Robicsek et al., 2006).  155 
 156 
E. coli isolates were selected for whole genome sequencing (WGS) based on evidence of 157 
phenotypic ESBL production; MDR status; presence of plasmid-associated AmpC, or plasmid-158 
associated fluoroquinolone resistance genes on PCR. Fragment libraries (NEBNext Ultra II FS 159 
Kit; ~300 base pair inserts) were created from purified genomic DNA (Qiagen QIAmp DNA 160 
mini kit) and sequenced using a 2x150 base pair paired-end protocol (Illumina HiSeq; CGR, 161 
University of Liverpool; GenBank accession numbers: supplementary material 4). De novo 162 
assembly was performed using SPAdes 3.16.0 (Bankevich et al., 2012), and genome annotation 163 
via Prokka 1.14.5 (Seemann, 2014). In silico identification of MLST and AMR genes were 164 
analysed via MLST 2.19.0 (Seemann, 2019), ABRicate 0.8 (Seemann, 2020a), and BLASTP 165 
searches. Core genome SNPs were determined via Snippy 4.4.5 (Seemann, 2020b); 166 
phylogenies were estimated via maximum likelihood phylogenetic analysis using raxml-ng 167 
(Kozlov et al., 2019), with a generalised time-reversible model and 1,000 bootstraps, and 168 
annotated using iTOL 4 (Letunic and Bork, 2019). Plasmids were identified via PlasmidFinder 169 
(Carattoli et al., 2014), summarising incompatibility (Inc) group plasmids with 100% coverage 170 
and >80% identity. 171 
 172 
Statistical analyses 173 
All statistical analyses were completed using R (v3.4.4). Descriptive proportions and 95% 174 
confidence intervals were adjusted for clustering within practice sites (bootstrap method, 175 
n=5,000 samples) (AOD, 2016). Mixed effects logistic regression models exploring odds of E. 176 
coli resistance were fitted separately in dogs and cats (LME4, 2016), considering 3rd/4th 177 
generation cephalosporin resistance as a binary outcome variable. MDR, fluoroquinolone and 178 
potentiated penicillin resistance were also modelled (supplementary material 5-13). Both 179 
practice site and VDL were included as random effects if a likelihood ratio test (LRT) 180 
suggested improved fit. Initial univariable screening considered a range of categorical 181 
explanatory variables, including sample type/site and animal or practice site demographic 182 
features (supplementary material 8). Explanatory variables were retained for multivariable 183 
analysis if a LRT indicated P≤0.20 against a null model. 184 
 185 
Multivariable models underwent step-wise backward elimination to minimise Akaike 186 
Information Criterion (AIC). Two-way interaction terms were retained if inclusion resulted in 187 
an AIC decrease. Multicollinearity was assessed using the Variance Inflation Factor (CAR, 188 
2018). Statistical significance was defined as P<0.05. 189 
 190 
Results 191 
AST Data – laboratories A-D 192 
Data were obtained for 29,330 canine and 8,279 feline Enterobacteriaceae isolates from 2,237 193 
practice sites, corresponding to 49.1% (95% confidence interval, CI, 47.7-50.6) of registered 194 
companion animal-treating sites (Supplementary material 14), contributing a median of seven 195 
canine (range 1-156) and three feline (range 1-166) isolates each. Though practice site details 196 
could not be ascertained in 6.7% (CI 5.3-8.1) of canine and 5.8% (CI 4.1-7.4) of feline AST 197 
reports, site demographic and animal population features of the remainder are summarised in 198 
Table 1 and Supplementary material 15, respectively. 199 
 200 
In total, 65 Enterobacteriaceae species were isolated (Supplementary material 16). E. coli was 201 
most common, representing 69.4% (CI 68.7-70.0) of canine, and 90.5% (CI 89.8-91.3) of feline 202 




of feline E. coli isolates; Supplementary material 17). MDR E. coli were reported in 14.1% of 204 
canine (CI 13.5-14.8) and 12.0% (CI 11.1-12.9) of feline isolates, MDR Proteus mirabilis in 205 
3.1% (CI 2.5-3.6) of canine, and 7.1% (CI 4.0-10.1) of feline isolates, and MDR Klebsiella 206 
pneumoniae in 21.3% (CI 15.3-27.4) of canine and 38.5% (CI 20.1-56.9) of feline isolates 207 
(Table 2). 208 
 209 
3rd/4th generation cephalosporin resistant E. coli 210 
While prevalence remained relatively stable over the two years summarised (Figure 1), 211 
geographical variation was observed (Figure 2). Male dogs were associated with reduced odds 212 
of 3rd/4th generation cephalosporin resistance, whereas male cats were associated with 213 
increased odds (Table 3). Practice sites examining referral cases only were associated with 214 
increased odds, as were RCVS accredited sites. Compared to urine samples, the anal region 215 
and oronasopharyngeal/respiratory samples were associated with increased odds in dogs and 216 
cats, respectively (univariable findings, supplementary material 18-19). 217 
 218 
Laboratory-based characterisation of resistant Enterobacteriaceae isolates 219 
 Referring laboratories 220 
In total, 146 isolates (130 canine, 16 feline) were submitted for further characterisation, 221 
including E. coli (n=106), P. mirabilis (n=12) and K. pneumoniae (n=10) (Supplementary 222 
material 4). Of these, 30.8% (CI 22.4-39.2) were indicated as having received antimicrobial 223 
therapy prior to sample submission, though 68.4%, (CI 60.2-76.6) were of unknown prior 224 
therapy status. Most isolates had been characterised via MIC (67.2% of isolates, CI 58.4-75.9), 225 
the remainder via disc diffusion (32.9%, CI 23.7-42.1). CLSI was the most utilised 226 
interpretation guideline (67.8%, CI 57.8-77.8), followed by EUCAST (19.8%, CI 9.9-29.7); 227 
BSAC (9.6%, CI 4.3-15.0), and CLSI-vet (2.7%, CI 0.0-5.3). 82.8% (CI 76.4-89.3) of isolates 228 
were reported by referring laboratories as MDR, and 97.8% (CI 95.4-100.0) were reported as 229 
phenotypically resistant to >1 3rd/4th generation cephalosporin, fluoroquinolones or 230 
polymyxins. An ESBL phenotype was indicated in 13.7% (CI 7.2-20.1) of submitted isolates, 231 
though 60.4% (CI 50.3-70.6) did not report an ESBL test. 232 
 233 
 University of Liverpool 234 
Phenotypic results from our laboratory showed MDR in 83.6% (CI 77.2-90.0) of isolates; 235 
71.3% (CI 63.7-78.9) were resistant to 3rd/4th generation cephalosporins and/or 236 
fluoroquinolones. An ESBL-producing phenotype was found in 34.2% (CI 26.3-42.2) of 237 
isolates (n=41 E. coli; n=5 K. pneumoniae; n=2 P. mirabilis; n=1 Proteus spp.; n=1 Citrobacter 238 
koseri), whereas a pattern suggestive of AmpC-production was observed in 8.9% (CI 4.2-13.6) 239 
of isolates (Supplementary material 4; n=11 E. coli; n=1 K. pneuomoniae; n=1 Enterobacter 240 
asburiae). 241 
 242 
Genomic analysis 243 
In total, 95 E. coli isolates were selected for WGS based on evidence of phenotypic ESBL 244 
production (n=38 isolates), MDR (n=68) and/or presence of plasmid-associated AmpC (n=24) 245 
or plasmid-associated fluoroquinolone resistance genes (n=6) on PCR (supplementary material 246 
4). 247 
 248 
Via WGS, MLST results were obtained from 91 E. coli isolates, identifying 38 sequence types 249 
(ST), most notably ST131 (n=10), ST162 (n=9), ST88, ST372, and ST1193 (n=5 each), ST73 250 
(n=3) and ST69 (n=3). In total, 17 clonal complexes (CC) were identified, most notably CC131 251 




phylogenetic analysis showed ST clustering, though no clear correlation between animal 253 
species or sampling site/type could be elucidated. 254 
 255 
An ESBL gene was detected in 28/38 phenotypic ESBL-producers. blaCTX-M genes 256 
predominated (n=27); blaCTX-M-15 was most common (n=15), followed by blaCTX-M-65  (n=4), 257 
blaCTX-M -27 (n=3), blaCTX-M-14 (n=3), blaCTX-M-9 (n=2), and blaCTX-M-1 (n=1). In addition, blaSHV-258 
12 (n=1) and the inhibitor resistant blaTEM-158 (n=2) and blaTEM-154 (n=1) were also detected. All 259 
ten ST131 isolates were associated with ESBL genes, with blaCTX-M-15 (n=7) most prevalent. 260 
Plasmid-associated AmpC genes were detected in 19 E. coli isolates, comprising blaCMY-111 261 
(n=11), blaDHA-1 (n=6), and blaCMY-42 (n=3). Of broad spectrum β-lactamases, blaTEM-105 was 262 
most common (n=29), followed by blaOXA-1 (n=17), blaTEM-150 (n=4), blaTEM-135, blaTEM-176 and 263 
blaTEM-190 (n=1 each). Two inhibitor resistant variants, blaTEM-30 (n=2) and blaTEM-34 (n=1), 264 
were also detected. 265 
 266 
Presence of both ESBL and AmpC or inhibitor resistant TEM variant enzymes in the same 267 
isolate can produce a phenotypic ‘masking’ effect on double disk ESBL testing, owing to the 268 
ability of AmpC to hydrolyse both clavulanic acid-potentiated and non-clavulanic acid 269 
potentiated cephalosporins (Jacoby, 2009). This can potentially result in an under-estimate of 270 
ESBL prevalence on phenotypic testing, as potentially shown here with non-phenotypic 271 
ESBL producers found to be carrying ESBL genes. This was likely due to a masking 272 
effect of inhibitor resistant blaTEM-154 in the first isolate; blaTEM-158 and blaCMY-42 in the second, 273 
and blaCTX-M-9 and blaCMY-111 in the third isolate. An ESBL gene was not detected in 10 274 
phenotypic ESBL E. coli isolates, with isolates carrying plasmid-associated AmpC (blaCMY-111, 275 
n=3; blaDHA-1, n=1) or broad spectrum β-lactamase (blaOXA-1, n=1) genes alone, or co-carried 276 
with blaCMY-111 and blaTEM-105 (n=2), blaCMY-42 and blaTEM-150 (n=1), blaCMY-111 and blaDHA-1 277 
(n=1), and blaDHA-1 and blaTEM-34 (n=1), respectively. An ESBL (blaCTX-M-14 and blaCTX-M-15) 278 
and AmpC (blaCMY-42) MDR isolate also carried the narrow-spectrum β-lactamase gene blaLAP-279 
2. 280 
 281 
Mutations in the gyrA, parC, or parE quinolone resistance determining region (QRDR) were 282 
found in 62 isolates. Twelve isolates carried plasmid-associated quinolone resistance genes 283 
(qnrA1, n=1; qnrB4, n=6; qnrS1, n=2; qnrS2, n=3), though only five had QRDR mutations, 284 
and none were associated with significant fluoroquinolone resistance. More broadly, the overall 285 
median number of AMR genes per isolate was 6 (range 0-13). Other prominent AMR genes 286 
included aadA1 (n=23), strA (n=34), strB (n=35), sul1 (n=35), sul2 (n=42), tetA (n=25), tetB 287 
(n=26), tetR (n=25) and dfrA17 (n=30). An ESBL (blaCTX-M-9) ST372 MDR isolate also carried 288 
a plasmid-mediated colistin resistance gene, mcr-9 (supplementary material 4). 289 
 290 
A median of 2 (range 0-4) Inc plasmids per isolate was found, with IncFIB being most 291 
numerous (n=59), followed by IncFII (n=35), IncI (n=25) IncFIA (n=14), IncY (n=5), IncR 292 
(n=3), IncX4 (n=3), IncX1 (n=2), and IncHI2 (n=1). Though plasmids were widely distributed 293 
across STs and resistance genes, nine of ten ST131 isolates possessed F-type plasmids (IncFIB, 294 
n=7; IncFII, n=7; IncFIA, n=5). Of blaTEM-105 isolates (n=29), 26 possessed IncFIB, and of 11 295 
blaCMY-111 isolates, 8 possessed IncFIB. The mcr-9 positive isolate had three plasmids: IncFIB, 296 
IncFII, and IncHI2, with IncH12 plasmids previously reported as associated with mcr-9 297 
(Kieffer et al., 2019). 298 
 299 
Discussion 300 
Here we have adopted an integrated health informatics and bioinformatics approach to conduct 301 




We have also demonstrated that clinical AMR isolates can be retained by VDLs and further 303 
characterised to reveal key AMR insights of one health importance. 304 
 305 
Resistance trends in Enterobacteriaceae are of critical importance to human health (Tacconelli 306 
et al., 2018). Considering the inherent one health nature of AMR (O’Neill, 2016), it is crucial 307 
to gain further understanding of AMR in our companion animal populations. Through collating 308 
AST results from half of companion animal-treating practice sites in the UK, with data being 309 
broadly comparative with both the estimated companion animal population (Aegerter et al., 310 
2017) and demographic features of the RCVS practice register (RCVS, 2018), we believe these 311 
data are nationally representative. However, mixed species practice sites were under-312 
represented in our dataset. Veterinary practitioners employed in different sectors (companion 313 
animal, farm etc.) have reported varied levels of support for ASTs (De Briyne et al., 2013), a 314 
disparity perhaps reflected in actual AST results here. Such findings can serve as a stimulus for 315 
localised resistance trend monitoring, potentially providing a powerful tool and motivator for 316 
antimicrobial stewardship. 317 
 318 
Antimicrobial classes rarely (or never) prescribed to companion animals, for example 319 
carbapenems (Singleton et al., 2017), were only rarely reported as being tested here. Critically 320 
important antimicrobials currently only used in medical practice should not be recommended 321 
for veterinary use. However, there would be value in routinely reporting resistance trends to 322 
such antimicrobials in veterinary isolates for public health purposes, as demonstrated by our 323 
findings relating to colistin resistance here. It should also be noted that differences between 324 
AST interpretation guidelines (e.g., EUCAST, CLSI) limited our ability to compare 325 
laboratories in this study, re-affirming a need for greater harmonisation between laboratories. 326 
AST data summarised here also does not include an individual animal identifier, hence it was 327 
not possible to designate multiple submissions originating from the same animal. To ameliorate 328 
this limitation, we would support efforts at increasing integration between practice and 329 
laboratory information management systems. 330 
 331 
Considering the above, individual class-level resistance prevalence was generally lower than 332 
reported in other studies, though MDR prevalence was broadly comparative (Marques et al., 333 
2016). While others have classified intermediate susceptibility results as resistant, potentially 334 
increasing resistance prevalence (VMD, 2019), doing so here would not have elevated findings 335 
to levels comparative with previous study (for example, re-classifying intermediate 336 
susceptibility findings as resistant would have increased E. coli 3rd generation cephalosporin 337 
resistance prevalence in dogs from 8.4% to 10.6%). Previous surveys have largely utilised data 338 
supplied by university-based diagnostic laboratories analysing referral populations (Hernandez 339 
et al., 2014; Marques et al., 2016), and here we found increased odds of resistance in isolates 340 
originating from referral-only practice sites for dogs. Antimicrobial use prior to culture has 341 
been shown to increase odds of isolating resistant bacteria (Hernandez et al., 2014). It is 342 
possible that antibiotic therapy prior to referral might in part explain these findings, suggesting 343 
a need to stratify surveillance into first opinion and referral populations, broadly in line with 344 
human surveillance (PHE, 2017). 345 
 346 
Considering animal-level features, genetic breed group, sex and neuter status were associated 347 
with 3rd/4th generation cephalosporin resistance odds variation in both species, . These findings 348 
potentially reflecting anatomical m(Hernandez et al., 2014) or behavioural differences (Chhetri 349 
et al., 2015) between animals, possibly resulting in increased likelihood of bacterial infection 350 
or resistance-selecting empirical antimicrobial prescription in some animalscases. Indeed, we 351 




Regarding sample type/site, the anal region in dogs and, oronasopharyngeal and respiratory 353 
samples in cats were associated with increased odds. Though resistant E. coli isolated from 354 
canine nasal or respiratory sites have been described (Morrissey et al., 2016), it has only rarely 355 
been implicated as a causative pathogen in human intensive care settings (de Lastours et al., 356 
2015). In dogs and cats, Enterobacteriaceae are considered minor components of oral, 357 
nasopharyngeal and respiratory microbiota, and their role as respiratory pathogens remains 358 
debatable (Dorn et al., 2017). Similarly, it is difficult to determine whether anal region samples 359 
reflect intestinal carriage or clinical infection, though could be considered to pose a public 360 
health risk, nonetheless. Several bacterial species usually considered contaminants were also 361 
reported within AST data (e.g. Kluyvera spp.; Pantoea spp. etc.); doing so without thorough 362 
evaluation of their association with infection is likely to encourage potentially unnecessary 363 
antimicrobial prescription. 364 
 365 
There are several Enterobacteriaceae resistance trends of critical one health importance, not 366 
least ESBL- or AmpC-production, fluoroquinolone resistance, carbapenemase producing 367 
Enterobacteriaceae, and colistin resistance (MacNair et al., 2018). However, due to the 368 
primarily clinical purpose behind AST results analysed here, some phenotypic tests were only 369 
rarely reported. Hence, here we aimed to investigate these isolates to gain further insight into 370 
dynamics of resistance development and transmission in the companion animal clinical 371 
population, utilising isolates supplied by multiple independent diagnostic laboratories. 372 
 373 
Regarding WGS findings, although ST372 E. coli has been previously primarily associated 374 
with canine infections and relatively rare resistance (Valat et al., 2020), here we identified an 375 
MDR ST372 also possessing mcr-9, a recently identified plasmid-associated colistin resistance 376 
gene (Carroll et al., 2019). In medical practice, colistin is considered an antimicrobial of ‘last 377 
resort’, and reported emergence of plasmid-mediated colistin resistance in 2015 instigated 378 
widespread concern (Liu et al., 2016). Although there is some debate regarding the clinical 379 
relevance of mcr-9 (Tyson et al., 2020) and when it first originated (Elbediwi et al., 2021), our 380 
finding represents its first identification in a companion animal, and the first identification of a 381 
plasmid-associated colistin resistance gene in companion animals in the UK. Although 382 
companion animals are not prescribed colistin in the UK, they are relatively frequent recipients 383 
of another member of the polymyxin class, polymyxin B (Singleton et al., 2017). Concern has 384 
been raised over whether such use might be selecting for colistin resistance (Scott et al., 2019), 385 
though this remains to be determined in Enterobacteriaceae. Nevertheless, these findings serve 386 
to further reinforce the role of companion animals as carriers of resistance mechanisms of 387 
public health importance, and the need for surveillance to highlight the emergence of such 388 
trends. 389 
 390 
A diverse collection of ESBL genes was were found in E. coli isolates undergoing WGS, with 391 
the blaCTX-M (1, 9, 14, 15, 27 and 65) family dominating. In people, blaCTX-M-14 and blaCTX-M-15 392 
are of greatest clinical importance (Canton et al., 2012), whereas agricultural species are more 393 
commonly associated with blaCTX-M-1 carriage (Abraham et al., 2018). In companion animals, 394 
blaCTX-M-1 (Wedley et al., 2017), blaCTX-M-14 (Sun et al., 2016)  and blaCTX-M-15 (Timofte et al., 395 
2016) have each been identified. Here blaCTX-M-15 was most prevalent; concerningly, the human 396 
pandemic clone ST131 predominated, further demonstrating links between people and 397 
companion animals for important resistance and pathogenic clones (Zhang, 2016). This clone 398 
has been detected in companion animal clinical isolates previously, and is considered a driver 399 
of blaCTX-M-15 dissemination in human and animal populations (Timofte et al., 2016). F-type 400 
Inc plasmids were also frequently identified, this group of plasmids (particularly IncFII) being 401 




resistant ESBL genes were also detected at low frequency, the blaTEM-158 gene having been 403 
previously reported in a companion animal referral hospital in the UK (Tuerena et al., 2016). 404 
 405 
Although less frequently identified than ESBL genes, AmpC genes were also identified in these 406 
isolates. Despite blaCMY-2 being the most well distributed blaCMY allele worldwide (Jacoby, 407 
2009), including in companion animals (Wedley et al., 2011), it was not detected here. Instead, 408 
the comparatively recently identified blaCMY-111 (Kao et al., 2018), representing the first 409 
identification in companion animals, and blaDHA-1, this gene only recently reported in European 410 
companion animals (Belas et al., 2014), were found to predominate. Although the blaCMY gene 411 
has many variants (Jacoby, 2009), and as such a measured view of this novel finding should be 412 
taken, our results do suggest increased AmpC diversity in companion animals. We also 413 
detected ST410 in this population, this ST being previously implicated in human and 414 
companion animal infection (Timofte et al., 2016), including harbouring a carbapenemase 415 
resistance gene in a sample of canine origin (Reynolds et al., 2019).  416 
 417 
Regarding treatment of ESBL and/or AmpC-mediated infections in companion animals, the 418 
appropriateness of using alternative agents, such as the carbapenems and piperacillin-419 
tazobactam, is a topic of ongoing debate in the medical field due to concerns surrounding 420 
developing resistance to these ‘last report’ agents (Tamma and Mathers, 2021). Indeed the 421 
prescription of such agents to companion animals is not recommended (BSAVA, 2018), 422 
severely limiting treatment options for such cases. Accordingly, whilst emergence of these 423 
troubling clinical resistance trends in companion animals is often viewed primarily through the 424 
lens of associated public health risk, it should also be remembered that enhanced treatment 425 
failure risk may well also carry an increased risk to animal welfare. 426 
 427 
Quinolone resistance mechanisms are relatively complex, and consist of interactions between 428 
chromosomal mutations and plasmid-mediated genes (Hamed et al., 2018). In this study, 429 
chromosomal mutations were commonplace, contrasting with the relative scarcity of plasmid-430 
mediated genes. This finding suggests a greater role of chromosomal mutations in conferring 431 
clinical resistance in companion animals, in agreement with previous study (de Jong et al., 432 
2018). Considering AMR genes identified more widely, although many of the AMR genes 433 
identified here are commonly associated with plasmid types frequently identified in this study, 434 
specific, in-depth investigation was out of the scope of this study. Hence, though unlikely, it is 435 
possible that some of the assumed transmissible AMR genes discussed here might be 436 
chromosomal in origin. 437 
 438 
Although this study was successful in identifying clinical isolates of one health importance, we 439 
revealed further evidence of AST method and interpretation variation between VDLs. When 440 
confirmatory additional testing was performed at the University of Liverpool, although a 441 
similar percentage of isolates were reported as MDR by referring laboratories (82.8%) to that 442 
found at Liverpool (83.6%), ESBL testing was only reported for a minority of referring VDLs, 443 
potentially systematically under-estimating the impact of ESBLs on companion animal 444 
practice, and the potential risk posed to public health. This is likely due notification of ESBL 445 
presence being of an arguably greater importance for public health/surveillance than for clinical 446 
decision making. Hence, we suggest an urgent need to harmonise standard AST testing 447 
procedures, methods, and interpretation more closely, including tests of primary public 448 
health/surveillance relevance, if companion animal clinical bacterial isolates are to be used for 449 







This study demonstrated a method by which clinical AST results could be repurposed for near 454 
real-time passive and active AMR clinical surveillance at a nationally representative scale in 455 
companion animals, providing insights of importance and use to both veterinary practitioners 456 
and public health. Using Enterobacteriaceae as an exemplar, we found MDR to be common, 457 
with prevalence remaining relatively static between 2016 and 2018. We also conducted a pilot 458 
study to determine whether MDR E. coli isolates could be efficiently retrieved from VDLs and 459 
further characterised at the University of Liverpool, revealing presence of resistance genes and 460 
sequence types of importance to human and animal health. 461 
 462 
Contribution to the field 463 
Antimicrobial resistance (AMR) is a globally important one health threat reducing the range of 464 
antibiotics available to treat bacterial infections in both people and animals. Resistant bacteria, 465 
and genes conveying resistant traits, are increasingly ubiquitous, and can be readily passed 466 
between people, animals and the environment. As such, it is important to understand the current 467 
impact of AMR across all species groups. However, whilst the medical and agricultural sectors 468 
have relatively well-established AMR surveillance systems in place, such a system is currently 469 
lacking in companion animals. Here we describe an AMR surveillance system for companion 470 
animals whereby commercially distinct veterinary diagnostic laboratories have voluntarily 471 
contributed both data and bacterial isolates, forming for the first time an efficient clinical 472 
resistance alert system in this hitherto neglected species group. We have demonstrated the 473 
effectiveness of this system with the exemplar of Enterobacteriaceae; a family of bacteria 474 
associated with arguably the most concerning clinical resistance developments worldwide, 475 
showing the presence of several resistance genes responsible for significant treatment failure 476 
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Table 1: Summary of the percentage of Enterobacteriaceae Aantimicrobial susceptibility 518 
testST results originating from a range of veterinary practice site categories, as defined by the 519 
Royal College of Veterinary Surgeons (RCVS) on 12th October 2018, compared against the 520 
percentage of veterinary practice sites in the full RCVS practice register. 521 
Variable Category 
Dog Cat RCVS practice register 
% a (95% CI b) % (95% CI) 
% of practice sites 
(95% CI) 
Species treated Dogs and cats 74.9 (72.2-77.6) 81.0 (78.1-83.9) 80.0 (78.8-81.2) 
Dogs, cats and equids 2.5 (1.5-3.5) 2.3 (1.3-3.4) 2.8 (2.3-3.2) 
Dogs, cats and farmed species 3.0 (1.9-4.1) 2.6 (1.4-3.8) 2.1 (1.7-2.6) 
Mixed 12.7 (10.7-14.8) 8.3 (6.3-10.2) 15.1 (14.1-16.1) 
RCVS c accreditation Accredited sites 49.8 (46.7-53.0) 52.9 (48.8-57.1) 42.5 (41.1-44.0) 
RCVS veterinary hospital Sites with hospital status 17.5 (14.4-20.7) 19.3 (14.5-24.1) 4.6 (4.0-5.2) 
Out of hours (OOH) providers Sites providing OOH only 5.5 (3.6-7.5) 4.9 (3.1-6.8) 2.3 (1.8-2.7) 
Referrals Sites providing referrals only 1.8 (0.6-2.9) 1.7 (0.6-2.9) 1.3 (1.0-1.6) 
First opinion and referral sites 1.2 (0.4-1.9) 1.1 (0.2-1.9) 0.8 (0.5-1.0) 
RCVS AVP cd Sites employing 1< AVP 23.3 (20.2-26.4) 25.7 (21.0-30.4) 13.6 (12.6-14.6) 
RCVS Specialist Sites employing 1< specialist 7.1 (4.9-9.4) 8.7 (4.3-13.0) 2.6 (2.1-3.1) 
Veterinary nurse (VN) training sites Sites training VNs 79.0 (76.8-81.2) 80.0 (77.2-82.8) 56.6 (55.1-58.1) 
Location Urban 77.5 (74.9-80.1) 84.2 (81.4-86.9) 71.9 (70.6-73.2) 
RCVS practice register match No match de 6.7% (5.3-8.1) 5.8% (4.1-7.4) - 
 Match to >1 site ef 3.9% (2.5-5.3) 3.6% (2.2-5.0) - 
a Percentage of Enterobacteriaceae AST results 522 
b 95% Confidence interval 523 
c Royal College of Veterinary Surgeons 524 
cd Advanced veterinary practitioner 525 
de Results associated with a postcode not matching the RCVS practice registry 526 






Table 2: Summary of canine and feline E. coli, P. mirabilis and K. pneumoniae clinical 528 




% a (CI) b n tested % (CI) n tested 
Resistant to 1 or more classes 34.8 (34.0-35.5) 
20343 
29.8 (28.7-31.0) 
7497 Resistant to 1 or 2 classes 20.6 (20.0-21.2) 17.8 (16.9-18.7) 
Resistant to 3 or more classes 14.1 (13.5-14.8) 12.0 (11.1-12.9) 
Aminoglycosides 2.4 (2.0-2.8) 7583 1.9 (0.9-3.0) 1141 
Amphenicols 5.3 (4.1-6.5) 1657 5.0 (0.9-9.1) 180 
Nitrofurantoin 0.7 (0.6-0.9) 11103 0.4 (0.2-0.5) 5845 
Polymyxins 2.4 (0.3-4.4) 336 0.0 24 
Fluoroquinolones 5.5 (5.0-6.0) 20341 2.2 (1.6-2.7) 7497 
Potentiated sulphonamides 10.1 (9.5-10.7) 18734 3.9 (3.3-4.5) 7339 
Tetracyclines 11.8 (11.2-12.4) 18016 5.2 (4.6-5.8) 7189 
Beta-lactams 33.3 (32.5-34.2) 20343 29.3 (28.1-30.5) 7497 
Extended spectrum penicillins 34.5 (33.5-35.4) 18654 28.8 (27.6-30.0) 7327 
1st/2nd gen. cephalosporins 13.3 (12.7-13.9) 20282 13.2 (12.3-14.1) 7484 
3rd/4th gen. cephalosporins 8.4 (7.9-9.0) 17020 7.2 (6.5-8.0) 6730 
Potentiated penicillins 12.7 (12.1-13.4) 20293 11.7 (10.8-12.6) 7489 
Carbapenems 0.0 75 0.0 12 
 P. mirabilis 
Resistant to 1 or more classes 26.0 (24.8-27.2) 
5326 
33.9 (28.3-39.6) 
268 Resistant to 1 or 2 classes 22.9 (21.8-24.1) 26.9 (21.5-32.4) 
Resistant to 3 or more classes 3.1 (2.5-3.6) 7.1 (4.0-10.1) 
Aminoglycosides 3.3 (2.5-4.1) 2017 4.2 (0.0-8.8) 72 
Amphenicols 8.5 (6.9-10.1) 1359 8.4 (0.0-17.4) 36 
Fluoroquinolones 4.0 (3.4-4.7) 5326 7.1 (3.7-10.5) 266 
Potentiated sulphonamides 13.6 (12.4-14.8) 3972 18.7 (13.6-23.8) 230 
Beta-lactams 18.0 (16.9-19.1) 5326 26.1 (20.8-31.4) 268 
Extended spectrum penicillins 21.8 (20.4-23.2) 3968 28.5 (22.8-34.3) 231 
1st/2nd gen. cephalosporins 4.6 (4.0-5.2) 5323 8.2 (4.8-11.6) 268 
3rd/4th gen. cephalosporins 1.6 (1.2-2.1) 3961 3.1 (0.9-5.2) 231 
Potentiated penicillins 0.1 (0.0-0.2) 4963 0.0 243 
 K. pneumoniae 
Resistant to 1 or more classes 31.3 (25.2-37.4) 
483 
46.6 (28.0-65.2) 
48 Resistant to 1 or 2 classes 10.1 (7.4-12.9) 8.3 (9.8-15.6) 
Resistant to 3 or more classes 21.3 (15.3-27.4) 38.5 (20.1-56.9) 
Aminoglycosides 4.7 (2.2-7.2) 274 11.6 (0.0-26.6) 34 
Amphenicols 9.3 (0.9-17.7) 53 0.0 9 
Nitrofurantoin 33.3 (25.9-40.7) 201 6.1 (0.0-17.8) 16 
Fluoroquinolones 18.5 (13.4-23.7) 483 32.2 (15.0-49.4) 48 
Potentiated sulphonamides 13.0 (7.7-18.2) 446 33.6 (17.7-53.0) 43 
Tetracyclines 17.4 (12.1-22.6) 426 35.3 (17.7-53.0) 41 
Beta-lactams 24.4 (18.4-30.4) 483 42.3 (23.0-61.7) 48 
1st/2nd gen. cephalosporins 24.0 (18.0-30.0) 483 40.1 (20.4-59.8) 48 
3rd/4th gen. cephalosporins 20.0 (13.8-26.1) 412 41.0 (21.8-60.2) 40 
Potentiated penicillins 21.2 (15.1-27.2) 483 38.5 (20.4-56.6) 48 
Carbapenems 0.0 6 0.0 3 
a Percentage of tested isolates resistant  530 




Table 3: Multivariable mixed effects logistic regression models displaying risk factors 532 
significantly associated with odds of an E. coli clinical isolate being classed as 3rd/4th generation 533 
cephalosporin resistant in dogs and cats. For both models, veterinary practice site (dogs, 534 
variance=0.22, standard deviation, SD, 0.47; cats, variance=0.74, SD=0.86) was modelled as a 535 
random effect; for dogs, laboratory site (variance=0.99, SD=1.00) was also included. 536 
Significant categories within a variable are emboldened. 537 
Variable Category β SE a OR b (CI) c P 
Dogs 
Intercept -2.45 0.59 0.09 (0.04-0.27)  
Sex Female - - 1.00 - 
Male -0.13 0.06 0.88 (0.78-0.99) 0.03 
Unspecified 0.16 0.16 1.18 (0.87-1.60) 0.30 
Genetic breed  
group d 
Retriever - - 1.00 - 
Ancient / spitz 0.46 0.22 1.59 (1.03-2.43) 0.04 
Crossbreed 0.28 0.11 1.32 (1.06-1.64) 0.01 
Herding -0.12 0.17 0.89 (0.64-1.23) 0.47 
Mastiff-like 0.35 0.12 1.41 (1.11-1.79) <0.01 
Scent hound 0.50 0.17 1.65 (1.18-2.29) <0.01 
Sight hound -0.36 0.29 0.70 (0.40-1.22) 0.21 
Small terrier 0.46 0.13 1.58 (1.21-2.05) <0.01 
Spaniel 0.26 0.11 1.30 (1.04-1.62) 0.02 
Toy 0.46 0.17 1.59 (1.14-2.20) 0.01 
Not yet genetically classified 0.14 0.13 1.15 (0.90-1.47) 0.27 
Unknown breed 0.22 0.12 1.25 (0.98-1.59) 0.07 
Working dog 0.44 0.15 1.56 (1.17-2.08) <0.01 
Species treated Dog & cat - - 1.00 - 
Dog, cat & equine 0.19 0.20 1.21 (0.82-1.76) 0.34 
Dog, cat, equine & farm -0.20 0.11 0.82 (0.66-1.01) 0.06 
Dog, cat & farm 0.12 0.19 1.13 (0.78-1.65) 0.53 
RCVS accreditation Not accredited - - 1.00 - 
Accredited 0.14 0.07 1.15 (1.01-1.32) 0.03 
Referrals only Not referrals-only site - - 1.00 - 
Referrals-only site 0.70 0.27 2.02 (1.20-3.42) 0.01 
Mixed site -0.34 0.33 0.71 (0.37-1.36) 0.31 
RCVS Specialist No RCVS specialist on site - - 1.00 - 
RCVS specialist on site 0.43 0.15 1.54 (1.16-2.06) <0.01 
Sampling type / site Urine - - 1.00 - 
Anal region (including anal sacs) 0.24 0.09 1.28 (1.08-1.51) 0.01 
Ear(s) 0.77 0.58 2.17 (0.70-6.75) 0.18 
Faeces 0.06 0.25 1.06 (0.65-1.75) 0.81 
Oronasopharyngeal & respiratory 0.12 0.22 1.13 (0.73-1.73) 0.59 
Other sites or mixed 0.63 0.07 1.87 (1.62-2.15) <0.01 
Cats 
Intercept  -3.20 0.24 0.04 (0.03-0.07)  
Sex Female - - 1.00 - 
Male 0.31 0.11 1.37 (1.11-1.68) <0.01 
Unspecified 0.06 0.30 1.06 (0.59-1.92) 0.84 
Genetic breed  
group e 
West Europe - - 1.00 - 
Asian 0.10 0.29 1.10 (0.62-1.96) 0.74 
Crossbreed 0.11 0.21 1.12 (0.74-1.70) 0.59 
Not yet genetically classified -0.41 0.37 0.66 (0.32-1.37) 0.27 
Unknown breed -0.35 0.26 0.71 (0.42-1.18) 0.19 
RCVS accreditation Not accredited - - 1.00 - 
Accredited 0.23 0.12 1.25 (0.98-1.60) 0.07 
Sampling type / site Urine - - 1.00 - 
Anal region (including anal sacs) 0.27 0.38 1.32 (0.63-2.75) 0.47 
Faeces -1.07 0.60 0.34 (0.11-1.11) 0.07 
Oronasopharyngeal & 
respiratory 
0.67 0.25 1.95 (1.19-3.18) 0.01 
Othe  sites or mixed 0.65 0.17 1.91 (1.38-2.63) <0.01 
a Standard error 538 
b Odds ratio 539 
c 95% Confidence interval 540 
d Vonholdt et al. (2010) 541 





Figure 1: Percentage of (a) canine and (b) feline Enterobacteriaceae AST results reporting 544 
single-class resistance (AMR); multi-drug resistance (MDR); 3rd/4th generation cephalosporin 545 
resistance (3GC); fluoroquinolone resistance (FQ), or potentiated penicillin resistance (POT 546 
PEN.) between the 2nd quarter of 2016 and the third quarter of 2018. Error bars refer to 95% 547 





Figure 2: Quintile bivariate postcode map displaying the proportion of tested isolates that were 550 
submitted by non-referrals / specialist veterinary practice sites recording phenotypic 3rd/4th 551 
generation cephalosporin resistance in (A) dogs and (B) cats. Proportions are displayed against 552 
standard error. Scale is in Km. The embedded histogram displays the proportion of tested isolates 553 







Figure 3: Maximum likelihood phylogenetic tree constructed by core genome SNPs of 91 558 
E.coli isolates using the genome of E. coli K12 as a reference. Coloured bands and numbers in 559 
the first column indicate clonal complex (CC) of the isolate (grey colour indicates unassigned 560 
CC). A heatmap represents antimicrobial susceptibility (red = resistance; yellow = 561 
intermediate; green = susceptible). Brown circles in columns six and eleven represent the 562 
presence of beta-lactamase genes and the mcr-9 gene respectively. The seventh - ninth columns 563 
represent QRDR mutations in gyrA, parC, and parE, respectively. The tenth column shows the 564 
presence/absence of the plasmid-mediated quinolone resistance gene, qnr, in each isolate. 565 
Purple squares in the last column indicate plasmid replicons identified in each isolate. 566 
Abbreviations for antibiotics tested here are as follows: AP = Ampicillin; AUG = Clavulanic 567 
acid potentiated amoxicillin; KF = Cephalothin; CPD = Cefpodoxime; C = Chloramphenicol; 568 
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